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Background: Pulmonary embolism (PE) with more than 50% compromise of pulmonary
circulation results significant right ventricular (RV) afterload leading to progressive RV
failure, systemic hypotension and shock. Prompt restoration of thrombolysis, surgical
embolectomy, or percutaneous mechanical thrombectomy (PMT) prevents progressive
hemodynamic decline. We report our single center experience in high risk PE patients
treated with standard pigtail catheter mechanical fragmentation followed by intra-
pulmonary thrombolysis as a primary therapy.
Methods: 50 consecutive patients with diagnosis of high risk PE defined as having shock
index >1 with angiographic evidence of >50% pulmonary arterial occlusion are included in
the present study. All patients underwent emergent cardiac catheterization. After ensuring
flow across pulmonary artery with mechanical breakdown of embolus by rotating 5F pigtail
catheter; bolus dose of urokinase (4400 IU/kg) followed by infusion for 24 h was given in the
thrombus. Hemodynamic parameters were recorded and follow up pulmonary angiogram
was done. Clinical and echo follow up was done for one year.
Results: Pigtail rotational mechanical thrombectomy restored antegrade flow in all patients.
Themean pulmonary artery pressure,Miller score, Shock index decreased significantly from
41 8mmHg, 20 5, 1.32 0.3 to 24.52 6.89, 5.35 2.16, 0.79 0.21 respectively (p< 0.0001).
In-hospital major complicationswere seen in 4 patients. There was a statistically significant
reduction of PA pressures from 62  11 mmHg to 236 mmHg on follow up.
Conclusions: Rapid reperfusion of pulmonary arteries with mechanical fragmentation by
pigtail catheter followedby intrapulmonary thrombolysis results in excellent immediate and
intermediate term outcomes in patients presenting with high risk pulmonary embolism.
Copyright ª 2014, Cardiological Society of India. All rights reserved.om (B. Mohan).
ciety of India. All rights reserved.
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highly variable presentation ranging from asymptomatic to
massive PE. Massive PEs are those that cause more than 50%
pulmonary arterial compromise, leading to right ventricular
failure, circulatory collapse, hypotension, and/or shock. Mor-
tality rate without treatment from massive PE is approxi-
mately 30 percent; usually within the first few hours of the
initial event.1e3
The goal of therapy in patients presenting with massive PE
is rapid recanalization of pulmonary arteries with thrombol-
ysis or embolectomy; to decrease right ventricular afterload
and reverse right ventricular failure and shock, decrease the
risk of recurrence, and prevent chronic thromboembolic pul-
monary hypertension.4,5 Intravenous Thrombolytic therapy is
the first-line treatment in patients with high risk PE present-
ing with cardiogenic shock and/or persistent arterial hypo-
tension.6 A substantial proportion of patients, however, may
not be eligible for Intravenous thrombolysis because of major
contraindications.7 Surgical embolectomy is an alternative
therapeutic option in patients in whom thrombolysis is
absolutely contraindicated or has failed. However number of
experienced tertiary care centers with around-the-clock
availability of emergency surgical embolectomy are
limited.8,9 Percutaneous catheter embolectomy or mechanical
fragmentation of proximal pulmonary arterial clots followed
by local thrombolytic therapy may be considered as a very
attractive alternative to surgical embolectomy and systemic
thrombolysis because of their capacity to establish pulmonary
blood flow rapidly. Several reports have shown that me-
chanical fragmentation combined with local thrombolysis is a
good therapeutic option for restoring pulmonary flow and
decreasing PAP; with comparable short term outcomes to
systemic thrombolysis.10,11 However information on long
term outcomes are limited in literature. We report here our
single center experience in high risk PE patients treated with
standard pigtail catheter mechanical fragmentation followed
by intrapulmonary thrombolysis on immediate and long term
hemodynamic and clinical outcomes.1. Patients and methods
1.1. Patient population
This was an open labeled, noncomparative, single center
experience. Approval for the study was obtained from local
Institutional Ethics Committee. Prospectively consecutive
patients presenting with clinical diagnosis of pulmonary
embolism and shock index12 (heart rate in beats per minute
divided by systolic blood pressure in mm of mercury, HR/SBP)
>1 from July 2006eJuly 2009 were enrolled in the trial. The
patients were admitted to ICU and written informed consent
was obtained. Bed side transthoracic echocardiography was
done to confirm the suspicion of pulmonary embolism, to
estimate pulmonary arterial pressure and to exclude right
atrial or ventricular thrombi. All patients underwent emer-
gent right heart catheterization and pulmonary angiography.
Patients who showed a rapid deterioration of their cardio-
pulmonary condition were put on oxygen supplementation
with noninvasive pressure support or intubation. Positiveinotropic and vasoactive support was initiated according to
the hemodynamic conditions. All patients underwent emer-
gent right heart catheterization and pulmonary angiography.
Inclusion criteria for the study were: Patients with angio-
graphically confirmed acute massive pulmonary embolism
with shock index >1, pulmonary arterial occlusion with >50%
involvement of the central (main and/or lobar) pulmonary
arteries (Miller index >0.5),13 and pulmonary hypertension
(mean pulmonary artery pressure >25 mmHg.
Exclusion criteria included patients with echocardio-
graphically confirmed right sided thrombi, Acute gastroin-
testinal bleeding, Electrolyte imbalance, Anticoagulation with
international normalized ratio >1.8 or severe coagulopathy,
Anaphylactoid reaction to contrastmedia, Acute stroke, Acute
renal failure or severe chronic nondialysis dependent kidney
disease, Unexplained fever or untreated active infection, Se-
vere anemia, Uncooperative patient.
A total of 50 consecutive patients (9 females, 41males) with
average age of 47  12 years were included in this study.2. Methodology
All pulmonary angiograms and therapeutic interventional
procedures were performed in cardiac catheterization labo-
ratory (Phillips Medical Systems; Netherlands). After giving
local anesthesia; 5F sheathwas introduced in the femoral vein
for procedure. Initially 5F multipurpose catheter was
advanced over 0.035-inch Teflon-coated guide wires under
fluoroscopic guidance and was used to measure right heart
and pulmonary artery pressures. Subsequently, 5F standard
pigtail catheter was used to obtain initial pulmonary angiog-
raphy with an injected volume of 30e40 mL using cine mode
with a frame rate of 25/s. Angiographic quantification of de-
gree of pulmonary artery involvement was assessed by the
Miller score. Miller score is calculated as the sum of obstruc-
tion and perfusion scores, ranging from 0 (best) to 34 (worst).
Calculation of the Miller obstruction score ranges from 0 to 16:
9 major segmental branches in the right PA (3 in the upper
lobe, 2 in the middle lobe, 4 in the lower lobe) and 7 major
branches in the left PA (2 in the upper lobe, 2 in the lingual, 3 in
the lower lobe). The presence of filling defect in any of these
branches is scored 1 point. The perfusion is scored by dividing
each lung into 3 zones (upper,middle, and lower), and the flow
into each zone is characterized as absent (3 points), severely
reduced (2 points), mildly reduced (1 point), or normal (0
points.) A Miller score of 17 or more indicates a greater than
50% obstruction of pulmonary vascular bed and forms an
angiographic definition of a massive PE. The Miller index is
Miller score divided by 34 (range 0e1.0).
After confirming the inclusion criteria, mechanical cath-
eter thrombectomy was initiated using a pigtail catheter. The
catheter was quickly spun manually so as to fragment the
central thrombus and establish initial flow into pulmonary
artery (Fig. 1). After ensuring initial flow, the pigtail was left in
place inside the same large proximal embolus for subsequent
local thrombolytic therapy. Initial bolus dose of Urokinase
(4400 IU/kg body weight) was given over 10 min followed by
continuous infusion of 4400 IU/kg/hr for 24 h. All patients
were monitored continuously for clinical and hemodynamic
Fig. 1 e Pulmonary angiography revealing A) total cut off of right pulmonary artery B) mechanical breakdown and
intrapulmonary urokinase administration and C) post procedural pulmonary angiography revealing restoration of
pulmonary flow in right pulmonary artery and its branches.
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recorded and shock indexwas calculated hourly for 24 h along
with arterial oxygen saturations by finger oximetry and pul-
monary arterial pressures to determine clinical success. All
patients returned to the catheterization laboratory after 24 h
of urokinase therapy for repeat pulmonary angiography fol-
lowed by removal of pigtail catheter and femoral venous
sheath. Follow up Miller scores at 24 h were calculated to
define angiographic success.
All major complications such as a perforation of the pul-
monary artery or cardiac structures, cardiac tamponade, cere-
bral vascular accident, or death were recorded. Cardiovascular
mortality was defined as death secondary to PE, acute myocar-
dial infarction, cerebral vascular accident, or sudden death.
Bleeding complications were considered major if any GI or
genitourinary bleeding associated with a 10% drop of hemato-
crit or need for transfusion, or intracerebral and retroperitoneal
bleeding.
In-hospital management and long term follow up: after
24 h all patients were treated with intravenous heparin ther-
apy followed by oral anticoagulation therapy with Coumadin
prior to hospital discharge. After hospital discharge, all pa-
tients were followed every 3 months. Outcomes analysis
included recurrent PE, hospital readmission or occurrence of
cardiovascular death. Repeat transthoracic echocardiography
was done at follow up of 3, 6 and 12months to document right
ventricular size and function as well as pulmonary artery
pressures.2.1. Statistical analysis
Continuous variables are expressed as mean with SD, and
nominal variables in frequencies and percentages. Values
before and after treatmentwere compared using theWilcoxon
nonparametric test; p < 0.05 was considered significant. We
compared heart rate, oxygen saturation, pulmonary artery
(PA) systolic blood pressure (BP), PA diastolic BP, PA mean BP,
SBP, DBP, MBP, Shock Index and Miller index before and after
the procedure using mean and standard deviation. p-Value
was calculated using paired t-test. We used analysis of vari-
ance to see the trend in shock index andmean PA pressure, atvarious time intervals after the procedure. pvalue for linear
trend was calculated using linear regression models. All sta-
tistical analyses were done using SAS 9.2.3. Results
There were total of 50 patients (82% males, 18% females) with
mean age 47  12 years. Baseline characteristics of the pa-
tients are described in Table 1. The most frequent risk factors
for pulmonary embolism were recent immobilization within
prior 4 weeks (44%) and development of DVT (70%). Com-
monest clinical manifestations were acute onset dyspnea
(100%) for 1/2 h to 15 days prior to admission associated with
tachycardia (100%). Mean heart rate was 126 beats/min; mean
systemic systolic BP was 101 mmHg, with calculated mean
shock index of 1.32. Forty percent of patients had SBP
<90 mmHg at the time of admission (Table 2). Other clinical
signs/symptomswere nonspecific EKG findings revealed sinus
tachycardia in all patients and S1Q3T3 pattern in 52% pa-
tients. Bed side Transthoracic Echocardiogram (TTE) was done
within 30 min of presentation and revealed RV dilation, RV
hypokinesis and/ormoderate/severe TR in all patients. Classic
MCcullen’s sign was seen in 76% of patients. Estimated mean
right ventricular systolic pressure was 62  11 mm of Hg.
Thirty six percent of patients required vasopressor drugs for
hemodynamic support. Seventy two percent of patient had
arterial oxygen saturation of equal to or less than 95% with
respiratory distress on admission. Twenty four percent were
managed with positive pressure ventilation while 4% required
mechanical ventilation (Table 1).
Ninety four percent of patients were taken to the cathe-
terization laboratory within 2 h of presentation. Initial pul-
monary angiograms performed revealed bilateral pulmonary
artery involvement in 86% of patients and sub total occlusion
of main pulmonary artery in 4% of patients.
Hemodynamic and angiographic parameters prior to and
following percutaneous mechanical fragmentation followed
by 24 h of local thrombolytic therapy with urokinase are
shown in Table 2 and Fig. 2. Prior to mechanical catheter
fragmentation and thrombolytic therapy tachycardia was
Table 1 e Baseline characteristics at diagnosis.
Characteristics Data
Patients 50
Age, years 47  12
Gender 41 male/9 female
Comorbidities:
Malignancy 0
Tuberculosis 5 (10%)
Intravenous drug addict 2 (4%)
Recent immobilization (last 4 weeks) 22 (44%)
Leg fracture 9 (18%)
Postoperative 3 (6%)
Febrile illness 10 (20%)
Presenting symptoms:
Dyspnea 50 (100%)
Chest pain 9 (18%)
Syncope 4 (8%)
Cough 4 (8%)
Hemoptysis 2 (4%)
Duration of symptoms (h) 84 (0.5e360)
Presenting Signs:
Tachycardia 50 (100%)
Systolic BP <90 mmHg 20 (40%)
Electrocardiographic findings:
Sinus tachycardia 50 (100%)
S1Q3T3 26 (52%)
Right axis deviation 23 (42%)
T- wave inversion V1eV4 12 (24%)
Atrial flutter 2 (4%)
Deep vein thrombosis: 35 (70%)
Echocardiographic findings:
Right ventricular hypokinesis 50 (100%)
Right ventricular/left ventricular (ratio >1) 50 (100%)
McCullen’s sign 38 (76%)
Thrombus in RVOT 2 (4%)
Moderate to severe TR 50 (100%)
Pulmonary artery systolic pressure (mmHg) 62  (11)
Time-hospital admission to initial fragmentation
<1 h 12 (24%)
1e2 h 35 (70%)
>2 h 3 (6%)
Treatment:
Positive pressure ventilation 12 (24%)
Intubation/mechanical ventilation 2 (4%)
Hemodynamic support with vasopressor drugs 18 (36%)
*Data are presented as mean _ SD or no. (%) unless otherwise.
Table 2 e Pre and 24 h post procedure measurements in 50 pa
Me
Measurement Before
HR (BPM) 125.18 (17.83) 93.
Saturation (%) 90.33 (6.78) 98.
PA SBP (mmHg) 65.1 (10.39) 37.
PA DBP (mmHg) 29.26 (8.53) 17
PA MBP (mmHg) 41.21 (8) 24.
SBP (mmHg) 100.52 (19.15) 120
DBP (mmHg) 67.24 (10.36) 78.
MBP (mmHg) 78.33 (11.89) 92.
Shock index (HR/SBP) 1.32 (0.31) 0.
Miller score 20.21 (4.88) 5.
*P-value based on paired t-test.
Is statistically significant compared to the value at 6 h at the 0.05 level.
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94% patients, and pulmonary hypertension (mean PAP
>25 mm of Hg) was present in 100% of patients.
After 24 h of therapy, a significant increase of bothMBP and
Sao2 was observed (78.3  11.8 mmHg vs. 92.3  10.4. mmHg,
p< 0.0001; and 90.3  6.7 mmHg vs. 98.1  2.1%, p < 0.0001), as
were a significant decrease in the shock index (1.32  0.31 vs.
0.79  0.21, p < 0.0001), Miller score (20.2  4.8 vs. 5.3  2.1,
p < 0.0001), and mPAP (41.2  8.0 mmHg vs. 24.5  6.8 mmHg,
p < 0.0001). Fig. 3 shows the 2 hourly trend in the shock index
after initiation of therapy. Shock index improved rapidly to
less than one after 8 h of initiation of thrombolytic therapy
although statistically significant improvement was initially
noted at 4 h of follow up from 1.32  0.31 at baseline to
1.12  0.24, p < 0.001. The trend towards improvement
continued over 24 h with statistically significant decline to
index below 1 at 10 h and 22 h (0.98  0.19 at 10 h and
0.81  0.18 at 22 h) (Table 3).
3.1. In-hospital outcome
Hemodynamic success based on shock index was achieved in
92% of our patients along with clinical improvement in 96%
patients. Themajor complication rate was 8% (n ¼ 4): 2 deaths
and 2 major hematoma requiring blood transfusion. Both
patients died from persistent shock, severemetabolic acidosis
and acute renal failure within 72 h of hospitalization. There
were no other complications such as perforation of the pul-
monary artery or right ventricle, cardiac tamponade,
myocardial infarction, cerebrovascular accident or sudden
deaths during the hospitalization phase. Minor complications
were seen in 10% (n ¼ 5) of patients: local hematoma in 4 pa-
tients (8%), femoral artery pseudoaneurysm in one patient.
3.1.1. Long-term clinical outcome
During the follow up period, 100% of the surviving patients
were discharged on oral anticoagulation. 2 patients developed
upper GI bleed and oral anticoagulation was stopped with
placement of IVC filter. One of these patients developed
recurrent fatal pulmonary embolism after 18 months of initial
presentation. At one year of follow up another 3 patients were
noncompliant with their regimen of anticoagulation. One of
these had recurrent pulmonary embolism.tients.
an (SD) p* value
After Difference
28 (13.31) 31.9 (15.06) <0.0001
18 (2.1) 7.85 (6.05) <0.0001
76 (10.58) 27.34 (8.75) <0.0001
.9 (6.04) 11.36 (8.37) <0.0001
52 (6.89) 16.69 (7.25) <0.0001
.2 (14.47) 19.68 (18.92) <0.0001
48 (9.94) 11.24 (11.06) <0.0001
39 (10.48) 14.05 (12.19) <0.0001
79 (0.21) 0.53 (0.28) <0.0001
35 (2.16) 14.85 (4.33) <0.0001
Table 3 e Mean Shock Index (HR/SBP) by hours after
treatment.
Time (h) n Mean shock index (SD)
Baseline 50 1.32 (0.31)
2 50 1.25 (0.27)
4 50 1.12 (0.24)a
6 50 1.08 (0.22)
8 50 0.99 (0.2)
10 50 0.98 (0.19)b
12 50 0.95 (0.19)
14 50 0.9 (0.18)
16 50 0.88 (0.17)
18 50 0.87 (0.17)
20 50 0.85 (0.19)
22 50 0.81 (0.18)c
24 50 0.8 (0.19)
a Difference is statistically significant compared to the value at
baseline.
b Difference is statistically significant compared to the value at 4 h.
c Difference is statistically significant compared to the value at
10 h.
Fig. 2 e Comparison of hemodynamic data before and after
24 h of therapy.
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months. All patients had sequential analysis of pulmonary
artery systolic pressure (PASP) by TTE at 3 months; 6 months
and one year follow up along with clinical assessment. As
shown in Table 4, there was a significant reduction of pul-
monary artery systolic pressure at three months by 26 mmHg
from time of presentation (62.3  11.1 to 36.6  8.3 mmHg).
There continues to be small but statistically significant drop in
PASP even at 6 and 12months from initial presentation (Fig. 4).4. Discussion
Acute massive pulmonary embolism is life threatening and
one of the most enigmatic diseases facing emergency medi-
cine. Recent statement by AHA onmanagement of pulmonary
embolism define massive PE as patients with sustained sys-
tolic blood pressure<90mmHg for at least 15min or requiring
inotropic support in absence of other identifiable causes. The
document also defines submassive PE with strain as anyFig. 3 e Trend of shock index over first 24 h of therapy.hypotension (SBP <90 mmHg) or Shock index >1.0 or respi-
ratory failure evidenced by clinical appearance distress with
SaO2 <95% or Borg score>8 and evidence of RV dysfunction
suggested by RV hypokinesis or estimated RVSP> 40 mmHg,
elevated biomarker values (e.g., troponins, BNP> 100 pg/mL or
pro-BNP >900 pg/mL).14 Based on this definition, 40% of pa-
tients in our series were with massive PE and 60% of patients
had submassive PE with significant RV strain.
The consensus statement recommends IV fibrinolytic
therapy for patients withmassive PE (Class IIa; Level of Evidence
B) and for patients with submassive PE judged to have clinical
evidence of adverse prognosis (Class IIb; Level of Evidence C)
only in patients with low risk for bleeding complications
which is significant limitation of Intravenous thrombolytic
therapy. Up to fifty percent of patients presenting with
massive PE may have absolute contraindications to IV
thrombolysis.7 As in our patient population 44% of patients
would not have been able to receive IV thrombolysis due to
contraindications. Mechanical thrombectomy or surgical
thrombectomy are the alternatives. The guidelines recom-
mend for patients with massive PE and contraindications to
fibrinolysis or who remain unstable after receiving fibrinolysis
fragmentation of clot in the main or lobar pulmonary arteries
alone or followed by local thrombolysis as an alternative (Class
IIa; Level of Evidence C) when emergency surgical thrombec-
tomy is unavailable or not preferred.14
There is no randomized trial comparing mechanical
thrombectomy with local intrapulmonary thrombolysis and
IV thrombolytics. Pooled analysis of results from 13 Placebo-
Controlled, Randomized Trials of various fibrinolytics vs. IV
heparin alone to treat acute PE showed no advantage of
fibrinolysis in reducing mortality or recurrent PE. However
when the analysis was restricted to patients with massive PE
only, a significant reduction in recurrent PE or death was
observed from 19.0% with heparin alone to 9.4% with fibri-
nolysis (odds ratio 0.45, 95% CI 0.22e0.90).15,16 Data from EM-
PEROR [Emergency Medicine Pulmonary Embolism in the
Real-World Registry]and other registries indicate a trend
Table 4 e TTE estimated Mean PA Systolic pressure (mmHg) by months after treatment.
Time (month) Mean PAS pressure (Mean  SD) p* Comparison set Change in PA p
0 62.33 (11.1) 0e3 26.29 (6.88) **
3 36.61 (8.3) 3e6 9.42 (5.61) **
6 28.29 (7.41) 6e12 5.32 (6.19) **
12 23.03 (6.37) <0.0001
*p-value for linear trend.
**p value for difference in means based on analysis of variance (comparisons significant at the 0.05 level).
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in patients with massive PE.3,7,17,18 In patients with sub-
massive PE IV Thrombolysis has not been shown to improve
mortality19,20 and expected mortality rate in this subgroup of
patients is around 3%.18 However 10% of patients with sub-
massive PE may develop hemodynamically significant right
heart failure.20 Limitations of thrombolytic therapies are
several absolute and relative contraindications. Even when
patients are pre-screened for absolute and relative contrain-
dications, there is significantly high rate of hemorrhagic
complications (up to 20%) including the risk of hemorrhagic
stroke.15,16 Another limitation of thrombolysis is the time (at
least 2 h) which is needed to complete the recommended tPA
infusion protocol and the delayed onset of lytic effect with its
variable efficacy in the presence of organized venous
thrombus in the pulmonary artery.
Catheter based techniques which frequently combine me-
chanical and pharmacologic therapy have distinct advantages
over IV thrombolysis. It offers an immediate predictableway to
recanalize thrombus in the main pulmonary trunk or major
pulmonary arteries without exposure to risks of IV thrombol-
ysis or cardiopulmonary bypass.21 Various angiographic or
pigtail catheter devices have been used to break apart large
centrally located emboli by direct mechanical action.22 The
pigtail catheter is universally available cheap and effective
device. Thegoal of therapy is breakdown the large central fresh
clot into multiple small fragments to achieve partial reperfu-
sion for thrombolysis to act and not complete removal of
thrombus. The proposed mechanisms of improved thrombo-
lytic action are increased exposure of fresh clot surfaces
caused by fragmentation accelerating the thrombolytic action.
In addition when there is total occlusion of pulmonary artery
occlusion by an embolus, any fluid infused will theoreticallyFig. 4 e TTE estimated pulmonary artery systolic pressures
(mmHg) on long term follow up.make only evanescent contact with thrombus and be washed
into the nonoccluded ipsilateral and contralateral pulmonary
artery. After fragmentation, infused thrombolytics will have
greater contact with the distal thrombus throughout the pul-
monaryarterial tree.23e27Ninety four percent of patients in our
series were treated in less than 2 h of presentation. Partial
Pulmonary artery reperfusion with rotating pigtail catheter
was achieved in all patients with immediate initial stabiliza-
tion of pulmonary as well as systemic hemodynamics and
arterial oxygen saturation. One disadvantage with catheter
fragmentation techniques is the risk of embolization of clot
fragments into distal pulmonary circulation with potential
deterioration in hemodynamics.28,29 However in our study, no
evidence of macroembolisation leading to deterioration of
hemodynamics or other complications as perforation of pul-
monary artery, right ventricle or cardiac tamponade were
noted during mechanical reperfusion.
All patients in our series received intrapulmonary throm-
bolysis for 24 h with repeated assessment of hemodynamics
every 2 h. Pulmonary perfusionwas assessed angiographically
at 24h.Although therewas immediate improvement inoxygen
saturation and pulmonary pressures with mechanical reper-
fusion alone, the shock index (systemic hemodynamics)
showed a gradual decline with statistically significantly fall
first seen only after 4 h and then a further decline to less than 1
at 10 h. At 24 h 98% of patients had improved systemic hemo-
dynamics with 92% having shock index <1. We believe me-
chanical reperfusion needs to be followed by catheter directed
thrombolysis to prevent progressive RV dysfunction and
development of cardiogenic shock.30 We also observed 41%
reduction in mean pulmonary artery pressure at 24 h paral-
leling 74% reduction in lung perfusion defect (Millers score
from 20.21  4.88 to 5.35  2.16). Although there are no ran-
domized trials comparing catheter based interventions vs. IV
thrombolysis, studies comparing IV fibrinolysis vs. heparin
alone show 30%e35% reduction in total lung perfusion defect
with fibrinolysis at 24 h compared to no substantial improve-
ment in pulmonary bloodflowwithheparin alone.However, at
7 days, both heparin and fibrinolysis groups showed similar
65%e70% reduction in total lung perfusion defect indicating a
continuous process of body’s own autothrombolysis.31 Our
observations andprevious studies using similar approachmay
suggest that catheter based therapies result in more rapid
improvement in lung perfusion and pulmonary artery pres-
sure compared to systemic thrombolysis and heparin alone.32
Although clinical success of catheter based techniques has
not been compared in a randomized trial with systemic
thrombolysis or anticoagulation alone, but it compares
favorably with the available data for systemic thrombol-
ysis.11,30 Kuo et al11 based on a recent meta-analysis of 594
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94 patients, 29 retrospective with 500 patients) reported
pooled clinical success rate from catheter based therapy to be
86.5% (95% CI: 82.2%e90.2%) when clinical success was
defined as hemodynamics stabilization, resolution of hypoxia,
and survival at hospital discharge. The success rate was
higher (91% vs. 83%) when local thrombolytic therapy was
used after mechanical fragmentation. Rotating pigtail cath-
eter was the most common device used for mechanical
intervention in 69% of the total study group. All 50 patients in
our series were treated with rotating pigtail fragmentation
followed by 24 h infusion of local thrombolytic therapy. Using
the same definition of clinical success, we observed a success
rate of 96%.
In addition, the meta-analysis of catheter derived therapy
where majority of patients treated had contraindication to IV
thrombolytic therapy show a comparably low risk of minor
procedural complications rate of 7.9% (95% CI: 5.0%e11.3%)
and major procedural complications rate of 2.4% (95% CI:
1.9%,e4.3%) with low incidence of intracranial bleeding.11 In
contrast, the summarized data from randomized trials show a
relatively high 13% rate of major bleeding and a 1.8% rate of
intracranial/fatal hemorrhage with fibrinolysis.15,16 In our
series, major hematoma requiring blood transfusion was seen
in 4% (n ¼ 2) and minor hematomas were seen in 8% (n ¼ 4) of
patients. None of our patients had intracranial hemorrhage,
other major bleeding complications or pulmonary artery/RV
injury. The observation reaffirms the low risk of major com-
plications associated with catheter based reperfusion therapy
for massive and high risk submassive pulmonary embolism
compared to IV thrombolysis despite the theoretically poten-
tial higher risk.
In literature, there is no prior well designed study of
catheter based therapy on its effect on right ventricular sys-
tolic pressure (RSVP) or estimated pulmonary artery pressure
and the development of chronic thromboembolic pulmonary
hypertension (CTEPH) at 1 year follow up. Some studies have
shown significant 46% reduction in pulmonary artery pres-
sures with no incidence of CTEPH at 3e6 months follow up.32
Similarly pooled analysis of the 4 reported studies showed a
significantly greater reduction in estimated pulmonary arte-
rial pressures with fibrinolysis plus heparin compared to
heparin alone (mean of 50% vs. 25% respectively) at 6 months
follow up.33e36 Butmore importantly the study by Kline et al 36
showed an increase in RVSP in 27% of the patients in heparin
group compared to none in fibrinolysis group indicating a
beneficial impact of thrombolysis on development of CTEPH.
In our present study, all surviving patients had sequential
follow up echocardiogram at 3, 6 & 12 months to assess RVSP.
Our data show a marked reduction in systolic pulmonary ar-
tery pressures from 62.33 11.1 at baseline to 28.29 7.4 (55%)
at 6 months follow up. On sequential analysis there was
further statistically significant improvement in PA pressures
at 1 year compared to at 6months post therapy (28.29 7.4 at 6
months to 23.03  6.3 at 1 year p < 0.0001) indicating a
continued long term pulmonary artery remodeling following
initial injury and recanalization of pulmonary vasculature.
Thismay suggest that an anticoagulation therapymay need to
be continued for up to a year to prevent repeat injury to pul-
monary arteries.5. Conclusion
The data form our single center largest reported prospective
study suggest that a rapid reperfusion of pulmonary arteries
with mechanical fragmentation by universally available pigtail
catheter followed by intrapulmonary thrombolysis over 24 h
results inexcellent immediateand intermediate termoutcomes
comparable to published results of IV thrombolysis in patients
presenting with massive or high risk submassive pulmonary
embolism. We believe a more aggressive invasive approach
after rapid initial clinical and echocardiographic evaluation
followed by immediate transfer to catheterization laboratory
offers a prompt diagnostic and potentially lifesaving therapeu-
tic approach in high risk group of patients with pulmonary
embolism. In addition, the approach is applicable to larger
group of patients with lower risk of complications compared to
IV thrombolysis. It can be offered as a primary therapy in
experienced centers, similar to approach with coronary revas-
cularization, in high risk patients with pulmonary embolism.
5.1. Limitation
Ours is a nonrandomized study with small sample size where
bias in choosingmanagement options can not be ignored. The
majority of our patientswere less than 60 years of agewith low
risk for intracranial and other hemorrhagic complications.Conflicts of interest
All authors have none to declare.
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Abbreviation used
PE: Pulmonary embolism
PAP: Pulmonary arterial pressure
HR: Heart rate
SBP: Systolic blood pressure
ICU: Intensive care unit
PA: Pulmonary artery
BP: Blood pressure
DBP: Diastolic blood pressure
MBP: Mean blood pressure
DVT: Deep vein thrombosis
EKG: Electrocardiogram
mPAP: Mean pulmonary artery pressure
PASP: Pulmonary artery systolic pressure
IVC: Inferior venacava
GI: Gastrointestinal
TTE: Transthoracic echocardiography
AHA: American Heart Association
RVSP: Right ventricular systolic pressure
BNP: Brain natriuretic Peptide
RV: Right ventricle
IV: Inferior venacava
CTPEH: Chronic thromboembolic pulmonary hypertension
